1. Home
  2. FMS vs VTRS Comparison

FMS vs VTRS Comparison

Compare FMS & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fresenius Medical Care AG

FMS

Fresenius Medical Care AG

HOLD

Current Price

$23.56

Market Cap

13.5B

Sector

Health Care

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$11.63

Market Cap

12.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FMS
VTRS
Founded
1996
1961
Country
Germany
United States
Employees
N/A
N/A
Industry
Misc Health and Biotechnology Services
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.5B
12.0B
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
FMS
VTRS
Price
$23.56
$11.63
Analyst Decision
Sell
Hold
Analyst Count
2
6
Target Price
$30.00
$11.50
AVG Volume (30 Days)
450.8K
7.4M
Earning Date
11-04-2025
11-06-2025
Dividend Yield
2.42%
4.12%
EPS Growth
8.62
N/A
EPS
2.86
N/A
Revenue
$23,046,819,198.00
$14,124,400,000.00
Revenue This Year
$2.12
N/A
Revenue Next Year
$2.92
$1.16
P/E Ratio
$15.93
N/A
Revenue Growth
2.10
N/A
52 Week Low
$22.05
$6.85
52 Week High
$30.46
$13.13

Technical Indicators

Market Signals
Indicator
FMS
VTRS
Relative Strength Index (RSI) 45.83 72.47
Support Level $22.63 $10.67
Resistance Level $24.20 $11.63
Average True Range (ATR) 0.27 0.25
MACD 0.10 0.09
Stochastic Oscillator 59.23 92.86

Price Performance

Historical Comparison
FMS
VTRS

About FMS Fresenius Medical Care AG

Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: